ReviewWiener klinische Wochenschrift2006
Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.
Review in Wiener klinische Wochenschrift, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.German medical science : GMS e-journal · 2025Guideline
- Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.German medical science : GMS e-journal · 2017Guideline
- The In Vitro Antimicrobial Susceptibility ofPathogens (Basel, Switzerland) · 2023Review
- Genetic Manipulation ofCurrent issues in molecular biology · 2021Review
- IL-26 mediated human cell activation and antimicrobial activity againstCurrent research in microbial sciences · 2020Article
- Lyme Disease Frontiers: ReconcilingPathogens (Basel, Switzerland) · 2019Review
- Antimicrobial Resistance inMicrobiology spectrum · 2018Review
- In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.BMC veterinary research · 2017Article
- Article
- Article
- Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.Emerging microbes & infections · 2014Article
- An optimized SYBR Green I/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferi.PloS one · 2014Article
- Population bottlenecks during the infectious cycle of the Lyme disease spirochete Borrelia burgdorferi.PloS one · 2014Article
- Genetics of Borrelia burgdorferi.Annual review of genetics · 2012Review
- High-throughput screening identifies three inhibitor classes of the telomere resolvase from the lyme disease spirochete.Antimicrobial agents and chemotherapy · 2009Article
- Borrelia burgdorferi resistance to a major skin antimicrobial peptide is independent of outer surface lipoprotein content.Antimicrobial agents and chemotherapy · 2009Article
- In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Lyme borreliosis is a multisystem disorder that can progress in stages and is transmitted by ticks of the Ixodes ricinus complex infected with the spirochete Borrelia burgdorferi sensu lato. Today, Lyme borreliosis is regarded as the most important human tickborne illness in the northern hemisphere. Soon after the causative agent was correctly identified and successfully isolated in 1982, antibiotic treatment was shown to be effective and since then a variety of in vitro and in vivo studies have been performed to further characterize the activity of antimicrobial agents against B. burgdorferi s.l. Although many antimicrobial agents have been tested for their in vitro activity against borreliae, the full spectrum of antibiotic susceptibility in B. burgdorferi s.l. has not been defined for many compounds. Moreover, our current understanding of possible antimicrobial resistance mechanisms in B. burgdorferi s.l. is limited and is largely founded on in vitro experiments on relatively few borrelial isolates. This review will summarize what is and what is not known about antimicrobial resistance in B. burgdorferi s.l. and will discuss open questions that continue to fuel the current debate on treatment-resistant Lyme borreliosis.
Indexed as
Identifiers
17160604What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.